Drug Trials Snapshots: VEOPOZ
VEOPOZ (pozelimab‑bbfg) received FDA approval on August 18, 2023 to treat CD55‑deficient protein‑losing enteropathy (CHAPLE disease) in patients of all ages. The decision was based on a single‑arm trial of ten patients enrolled in Turkey, Thailand and the United States, with a demographic mix of 40% male, 70% White and a range of ages from 3 to over 12 years. All participants achieved normalized serum albumin and immunoglobulin G levels within 12 weeks, along with reduced transfusion needs and hospital days. Common side effects included respiratory infections, fractures, hives and alopecia, while serious infection risk remains a concern.
Axsome Gets FDA Approval for First Non-Antipsychotic Drug to Treat Agitation Associated with Alzheimer’s Dementia
The FDA has expanded the indication for Axsome Therapeutics’ Auvelity, approving it to treat agitation associated with Alzheimer’s disease dementia. This marks the first non‑antipsychotic medication cleared for this distressing symptom. Auvelity, originally approved in 2022 for major depressive disorder,...
FDA Proposal Would Exclude Bulk Compounding of Weight-Loss Drugs Semaglutide, Tirzepatide, and Liraglutide
The FDA announced a proposal to remove semaglutide, tirzepatide and liraglutide from the 503B bulk drug list, concluding there is no clinical need for outsourcing facilities to compound these GLP‑1 weight‑loss agents from bulk substances. Because FDA‑approved versions are already...
When a Species’ Survival Hinges on Every Single Embryo
The northern white rhino is functionally extinct, with only two non‑reproductive females left. BioRescue has produced 39 embryos using frozen sperm and eggs harvested from the remaining female, Fatu, but surrogate pregnancies in southern white rhinos have failed. A new...
Drug Trials Snapshots: EXXUA
Fabre‑Kramer Pharmaceuticals received FDA approval for EXXUA (gepirone) on September 22, 2023 as a once‑daily oral antidepressant for adult major depressive disorder. The approval was based on two placebo‑controlled, flexible‑dose Phase III trials that enrolled 456 patients, with 442 forming the...
The Future of Biomanufacturing: Key Highlights From INTERPHEX 2026
INTERPHEX 2026 highlighted a rapid shift toward digital integration and smarter single‑use technologies in biomanufacturing. Panels emphasized automation, continuous processing, and real‑time monitoring as ways to boost scalability while tackling data‑driven control challenges. A second discussion focused on supply‑chain resilience,...
Drug Trials Snapshots: POMBILITI
The FDA approved POMBILITI (cipaglucosidase alfa‑atga) on September 28, 2023 for adult patients with late‑onset Pompe disease (LOPD) weighing ≥ 40 kg who are not responding to existing enzyme replacement therapy. Approval is based on a randomized, double‑blind trial of 123 participants across 61 sites...
ESOC 2026: What to Expect in Maastricht
The 12th European Stroke Organisation Conference (ESOC) convenes in Maastricht from May 6‑8, drawing roughly 4,200 delegates from 100 nations. Six scientific tracks will showcase the latest clinical trial data on stroke prevention, diagnosis, and treatment, including late‑breaking sessions on pre‑hospital...
FDA's Oncology Advisors Vote Against 'New Paradigm' In AstraZeneca Trial
The FDA’s oncology advisory committee voted 6‑3 that AstraZeneca’s late‑stage trial of camizestrant, an oral selective estrogen‑receptor degrader (SERD), did not demonstrate a clinically meaningful benefit. AstraZeneca had positioned camizestrant as a potential first‑in‑class oral therapy for hormone‑receptor‑positive metastatic breast...
Exclusive eBook: Inside the Stealthy Startup that Pitched Brainless Human Clones
MIT Technology Review released a subscriber‑only eBook exposing R3 Bio, a stealth biotech startup that pitches "brainless clones"—human bodies without brains—to serve as backup vessels for longevity seekers. The company envisions these clones as disposable shells that could host a...
Genmab A/S (NASDAQ:GMAB) Upgraded at Truist Financial
Truist Financial upgraded Danish biotech Genmab A/S (NASDAQ:GMAB) to a strong‑buy, joining recent upgrades from Goldman Sachs and BNP Paribas. The stock currently trades around $26.11, well below its 52‑week high of $35.43, with a market cap of $16.78 billion and a...
Synthetic Biologist Reza Kalhor Receives $250,000 President's Innovation Award
Synthetic biologist Reza Kalhor received the $250,000 President’s Innovation Award at Johns Hopkins University, recognizing his work on genomic recording technologies that capture biological events in DNA. His approach enables scientists to trace how early‑life signals contribute to diseases such...
BIO Panel at HERS Explores Women’s Health Biotech Ecosystem
The Biotechnology Innovation Organization (BIO) convened a panel at the inaugural Health Executive and Research Summit in San Diego to spotlight the women’s health biotech ecosystem. Speakers noted that only six percent of private healthcare investment goes to women’s health,...
Novartis Finalizes US Expansion with Seventh Facility to Strengthen End-to-End Drug Manufacturing
Novartas has completed its US expansion plan by adding a seventh facility in Morrisville, North Carolina, dedicated to API production for oral solid‑dose and RNA‑based therapies. The site is part of a $23 billion multi‑year investment to build an end‑to‑end domestic...
Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials
Avalyn Pharma completed a $300 million IPO, pricing 16.6 million shares at $18 each and listing on Nasdaq under the ticker AVLN. The Boston‑based biotech will use the proceeds to advance inhalable versions of pirfenidone (AP01) and nintedanib (AP02), plus a combination...
FDA Expedites Review of New HIV Treatment Combo
The FDA has granted priority review to Gilead Sciences’ new single‑tablet HIV regimen that combines bictegravir and lenacapavir. The application is backed by phase 3 ARTISTRY‑1 and ARTISTRY‑2 trials, which showed sustained viral suppression in adults already virologically controlled. If approved,...
Merck Still Sees ‘Compelling’ Outlook for Terns Leukemia Drug
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, paying $53 per share, after updated trial data showed its TERN‑701 leukemia drug achieving a major molecular response (MMR) rate north of 50% at 24 weeks. The data suggested TERN‑701 could outperform...
Other News to Note for April 30, 2026
Chinese biotech companies have reached an inflection point, gaining leverage as co‑dealmakers in cross‑border partnerships, according to multinational executives. Roche announced the discovery of new TREM2 agonist compounds aimed at modulating microglial activity for neurodegenerative diseases. Plasticity launched an advanced...
The Bangui Operation: A Story of Blood, Science and Biomedical Exploitation
In the early 1990s the Pasteur Institute in Bangui ran a covert HIV‑vaccine trial that recruited roughly 3,000 Central African soldiers, extracting over 11,000 blood samples. The research was funded by French institutions and aimed to fast‑track vaccine development at...
STAT+: Five-Way Obesity Drug Is Super Effective — in Mice
Researchers have unveiled a preclinical obesity candidate that combines five distinct mechanisms, delivering dramatic weight loss in mouse models and outperforming current GLP‑1 therapies. The multi‑modal approach targets appetite, metabolism, gut hormones, energy expenditure, and adipose tissue remodeling, achieving up...
Swiss BioTech Startup ALP Bio Raises €1.9 Million to Advance Immune Organoid and AI Platform
Swiss startup ALP Bio announced a €1.9 million (≈$2.1 million) pre‑seed round led by 42CAP to accelerate its immune organoid‑AI platform for antibody development. The platform couples human tonsil organoid readouts with generative AI to predict and reduce immunogenicity risk earlier in...
Zealand Pharma and Roche Advance Petrelintide to Phase 3 for Chronic Weight Management
Zealand Pharma and Roche are moving the amylin analog petrelintide into Phase 3 trials to treat chronic overweight and obesity. The drug achieved up to 10.7% mean weight loss in the Phase 2 ZUPREME‑1 study, with tolerability comparable to placebo. A March 2025...
FDA Proposes Excluding Novo, Lilly Weight Loss Drugs From Bulk Compounding List in Win for the Companies
The FDA has proposed removing the active ingredients of Novo Nordisk’s semaglutide and liraglutide and Eli Lilly’s tirzepatide from the bulk‑compounding list used by 503B outsourcing facilities. If the rule is finalized, these high‑demand obesity and diabetes drugs could only be...
Water Molecules Found to Actively Drive Gene Transcription Process
Researchers used sub‑2 Å cryo‑electron microscopy to map individual water molecules inside RNA polymerase II, revealing over a thousand waters positioned at catalytic sites. The study shows these waters actively mediate proton transfer, substrate recognition, and structural stabilization during transcription. This challenges...
Canada’s Life Sciences Sector Welcomes Federal Economic Update’s Focus on SR&ED Implementation
BIOTECanada welcomed the 2026 Spring Economic Update, which confirms the rollout of SR&ED administrative reforms first announced in Budget 2025. The changes raise the annual expenditure limit and taxable‑capital phase‑out thresholds for the enhanced 35% credit, extend the credit to...
GLP-1s May Prevent Incident AF, Series of Studies Shows
Observational analyses presented at Heart Rhythm 2026 suggest GLP‑1 receptor agonists, including tirzepatide, lower the risk of incident atrial fibrillation by 33%‑47% across diverse patient groups. The benefit appears consistent in individuals with or without diabetes, obesity, and chronic kidney...
Why Protocol Complexity Keeps Increasing – and How to Fix It
Protocol complexity in late‑stage trials is spiraling, with Phase III studies now averaging about 6 million data points—a rise of roughly 11% each year. The growth is fueled by scientific advances, global regulatory demands, and the ease of capturing extra data via...
Researchers Create DNA 'Nano-Rings' To Control Viral Cell Proteins
Scientists at Durham University and Jagiellonian University have engineered DNA‑origami nano‑rings that trap individual membrane proteins within nanodisks, creating a highly controllable platform for structural studies. The DNA‑Origami‑Constrained Nanodisks (DOC‑NDs) reliably capture single proteins and can dictate their orientation, a...
Five Companies Pushing Biotech in Scotland
Scotland’s life‑science sector now comprises roughly 750 companies and 46,000 employees, anchored by strong university spin‑outs in Edinburgh, Glasgow and Dundee. Within this ecosystem five biotech firms are drawing attention: Cumulus Oncology’s portfolio‑driven oncology asset creation, EnteroBiotix’s microbiome‑based IBS therapy...
BeOne Receives the US FDA Priority Review to Tevimbra Combination for 1L Treatment of HER2+ GEA Cancers
The U.S. FDA granted priority review to BeOne Medicines’ Tevimbra‑Ziihera‑chemotherapy regimen for first‑line treatment of unresectable HER2‑positive gastric, gastro‑esophageal junction and esophageal adenocarcinomas. The decision follows the Phase III HERIZON‑GEA‑01 trial, which enrolled 914 patients and compared the new combos against...
Canada First in G7 to Approve Generic Ozempic
Health Canada has granted approval for the first generic version of semaglutide, the active ingredient in Ozempic, making Canada the first G7 nation to do so. The generic injection, submitted by Dr. Reddy’s Laboratories, is indicated for once‑weekly treatment of adult...
RAAS Inhibitors Show Benefits in Pediatric CKD Vs. CCBs
A new comparative‑effectiveness study of 2,762 children with chronic kidney disease (CKD) found that renin‑angiotensin‑aldosterone system (RAAS) inhibitors significantly outperformed calcium‑channel blockers (CCBs) in preventing progression to dialysis or transplant. Over a two‑year follow‑up, RAAS users had a 42% lower...
NDMA: A Cancer-Causing Contaminant in Meds and Meat
The FDA has identified the probable carcinogen N‑nitrosodimethylamine (NDMA) in several high‑volume drugs—including valsartan, Zantac (ranitidine) and certain metformin formulations—prompting recalls and market withdrawals. NDMA exposure limits are set at 96 nanograms per day, yet a half‑chicken breast cooked by...
Doubts Cast over 'Wild' Claim that Magnetic Control Can Turn on Genes
Researchers in South Korea announced a magnetically controlled switch that can turn on genes inside cells using an electromagnetic signal, a development touted as a potential breakthrough for non‑invasive therapies. The study appeared in a leading journal but has been...
Colossal Biosciences Plans to De-Extinct the Bluebuck Antelope
Colossal Biosciences announced a new de‑extinction project targeting the bluebuck, an antelope that vanished in the early 1800s. Using CRISPR‑based gene editing and cloned embryos, the company aims to reintroduce a living specimen within the next decade. The bluebuck joins...
Is This ‘De-Extinction’ Project Actually Onto Something?
Dallas‑based biotech startup Colossal, backed by hundreds of millions of dollars from venture capitalists, the CIA and Peter Thiel, continues its high‑profile “de‑extinction” agenda. After controversial dire‑wolf hybrids, the firm announced a bluebuck project that focuses on a novel “ovum pickup”...
Symptom Progression Slowed in Lewy Body Dementia with Zervimesine
Cognition Therapeutics reported that the oral, brain‑penetrant small‑molecule zervimesine slowed symptom progression in a phase 2 SHIMMER trial of 130 adults with mild‑to‑moderate dementia with Lewy bodies (DLB). Over six months, patients receiving 100 mg or 300 mg daily showed 52‑86% slower decline...
Laguna Biotherapeutics Reports the US FDA IND Clearance for LGNA-100 to Treat High-Risk Pediatric Leukemias
Laguna Biotherapeutics announced that the U.S. Food and Drug Administration has granted IND clearance for its lead candidate LGNA-100, allowing the company to begin a Phase‑I single ascending dose trial. The study will evaluate safety, tolerability and mechanism of action...
'Two Lives Hang in the Balance': Risky Surgery in the Womb Saved Baby From Deadly Disorder at Just 25 Weeks...
Doctors at Orlando Health performed the first ex‑utero intrapartum treatment (ExIT) at 25 weeks to rescue a fetus with congenital high airway obstruction syndrome (CHAOS). The team created a tracheal catheter, drained fluid‑filled lungs, and returned the baby to the...
In Vitro Reconstruction of Axonal Heat Sensing with a Photothermal Nerve‐on‐a‐Chip
Researchers unveiled a photothermal nerve‑on‑a‑chip that couples graphene‑based microheaters with microelectrode arrays to deliver millisecond‑scale, localized heat to sensory axons while recording extracellular action potentials. The system captured rapid, reproducible heat‑evoked firing in rat dorsal root ganglion neurons and revealed...
FDA Advises Users of Trividia Glucometer to Switch to Alternatives
The FDA has issued a safety communication urging all users of Trividia Health’s True Metrix glucometer to switch to alternative blood‑glucose testing methods. The recommendation follows an error‑code flaw that displays the same E‑5 code for dangerously high glucose levels...
Huahui Health and BeOne Medicines Partner for HH160 in a ~$2.02B Deal
Huahui Health and BeOne Medicines have signed a global exclusive option, license and collaboration agreement for HH160, a novel trispecific antibody targeting oncology immunotherapy. Huahui will receive $20 million upfront, $100 million when BeOne exercises its option, and up to $1.9 billion in...
Real World Applicability of Ivermectin vs Permethrin Trial for Scabies
A recent cluster‑randomised trial found oral ivermectin more effective than 5% permethrin cream for treating classic scabies under controlled conditions. The study, however, enrolled participants from well‑resourced health centres and excluded severe dermatological cases, raising questions about its relevance to...
South African Startup Scales Up Growth Factor for Low-Cost Cultivated Meat
South Africa’s biotech startup Immobazyme, in partnership with the government‑run CSIR, has successfully scaled production of fibroblast growth factor 2 (FGF‑2) using a 50‑litre bioreactor. The protein, a costly growth factor essential for cultivated‑meat cell culture, was produced at commercial‑grade...
Buried in Soil, a 100-Million-Year-Old Bacterial Toxin Could Reshape Pest Control and Antibiotic Discovery
Researchers from McMaster, Harvard, Yale and European partners have identified a new class of insect‑killing proteins, SAIPs, produced by rare Streptomyces strains. These toxins, structurally distant from diphtheria toxin, target an insect‑specific surface protein called Flower, leaving humans unharmed. The...
EnVVeno Medical Secures FDA IDE Approval for Venous Valve Study
enVVeno Medical has secured FDA investigational device exemption (IDE) approval to launch its pivotal Transcatheter Venous Valve Endoprosthesis (TAVVE) study, targeting severe chronic venous insufficiency (CVI). The trial will begin later this year with a ten‑patient safety cohort, followed by...
Precision Begins Patient Enrolment for FUNCTION-DMD Trial
Precision BioSciences has activated Arkansas Children’s Hospital as the inaugural site for its Phase I/II FUNCTION‑DMD trial, enrolling boys aged two to seven with Duchenne muscular dystrophy. The study tests PBGENE‑DMD, a first‑in‑class in‑vivo gene‑editing therapy that removes exons 45‑55 to restore...
How Epic Bio Is Leveraging CRISPR without Cutting DNA
Epic Bio, founded by Stanford professor Stanley Qi, is developing an epigenetic editing platform called GEMS that uses the smallest known Cas protein to modulate gene expression without cutting DNA. The system can be delivered in a single viral vector...
Re: Efficacy and Safety of VPM1002 and Immuvac in Preventing Tuberculosis: Phase 3 Randomised Clinical Trial (PreVenTB Trial)
The phase‑3 PreVenTB trial found that neither VPM1002 nor Immuvac reduced microbiologically confirmed tuberculosis, missing its primary efficacy endpoint. The authors of a BMJ rapid response highlight that the headline claim of 50% efficacy against extrapulmonary TB rests on only...
Henlius and Organon Receive the EC Approval for Poherdy (Biosimilar, Perjeta)
The European Commission has granted approval for Poherdy, a 420 mg/14 mL interchangeable biosimilar of pertuzumab (Perjeta), covering all approved indications. The decision rests on extensive analytical, pharmacokinetic, efficacy, safety and immunogenicity data that demonstrate equivalence to the reference product. Henlius has...